Fidelity Investments
NGNE icon

Fidelity Investments’s Neurogene NGNE Stock Holding History

Fidelity Investments’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.3M Sell
295,561
-87,086
-23% -$2.4M ﹤0.01% 2162
2026
Q1 		$7.71M Buy
382,647
+252,318
+194% +$4.89M ﹤0.01% 2136
2025
Q4 		$2.68M Buy
130,329
+14,779
+13% +$368K ﹤0.01% 2502
2025
Q3 		$2M Sell
115,550
-352,926
-75% -$7.09M ﹤0.01% 2544
2025
Q2 		$7M Buy
468,476
+5,597
+1% +$87.8K ﹤0.01% 2056
2025
Q1 		$5.42M Sell
462,879
-397,454
-46% -$6.9M ﹤0.01% 2115
2024
Q4 		$19.7M Buy
860,333
+128,532
+18% +$4.78M ﹤0.01% 1734
2024
Q3 		$30.7M Buy
731,801
+659,515
+912% +$25.6M ﹤0.01% 1561
2024
Q2 		$2.63M Buy
+72,286
New +$2.55M ﹤0.01% 2277
2022
Q3 		– Hold
0
– – – 5235
2022
Q2 		– Sell
-60
Closed -$1.46K – 5304
2022
Q1 		$2K Buy
+60
New +$3.5K ﹤0.01% 4686

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Fidelity Investments's NGNE Position: Q2 2026 in Review

Fidelity Investments reduced its Neurogene (NGNE) stake by 23% in Q2 2026, selling an estimated $2.4M and leaving 295,561 shares worth $9.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2162.

Fidelity Investments first reported a position in NGNE in Q1 2022 and has held it in 10 quarters since. The position peaked at $30.7M in Q3 2024. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • Fidelity Investments held 295,561 shares of Neurogene worth $9.3M as of Q2 2026.
  • Fidelity Investments sold 87,086 Neurogene shares in Q2 2026, an estimated $2.4M.
  • Neurogene made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #2162 holding.
  • Fidelity Investments first reported a position in Neurogene in Q1 2022 and has held it in 10 quarters since.
  • Fidelity Investments's Neurogene position peaked at $30.7M in Q3 2024.
  • 112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.